New accents in type 2 diabetes melitus management: early prevention of cardiorenal complications


DOI: https://dx.doi.org/10.18565/therapy.2020.8.55-63

Demidova T.Yu., Zenina S.G.

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow
Diabetes mellitus (DM) is a proven risk factor for cardiovascular diseases (CVD) associated with a double increase of the probability of chronic heart failure (CHF) development in male and a five-time increase in female patients. In addition, most diabetic patients develop diabetic nephropathy, which also increases the risk of CVD. These complications can occur at all stages of the diabetic genesis of chronic kidney disease (CKD). Accordingly, a close bi-directional effect of the cardiovascular system on kidneys was determined – so called cardiorenal continuum. Pathogenesis of the cardiorenal continuum in patients with type 2 diabetes mellitus is multifactorial and depends on traditional risk factors, metabolic changes, and oxidative stress.
Inhibitors of the type 2 sodium glucose co-transporter, dapagliflozin, in particular, have shown the ability to reduce the risks of cardiovascular complications and CKD progression in patients with type 2 diabetes melitus. By now, a considerable experience has been accumulated in the use of dapagliflozin for type 2 diabetes patients’ treatment, both with already fixed atherosclerotic CVD, and also with only multiple risk factors. Dapagliflozin is able to positively influence at the entire cardiorenal continuum in patients with type 2 diabetes melitus, leading then to significant improvements.
Keywords: type 2 diabetes mellitus, cardiovascular complications, heart failure, chronic kidney disease, cardiorenal continuum, type 2 sodium glucose co-transporter inhibitors, dapagliflozin
Read entire article

Literature


  1. IDF Diabetes Atlas. 9th edition. 2019. URL: https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf (date of access – 01.11.2020).

  2. Шестакова М.В., Викулова О.К., Железнякова А.В. с соавт. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019; 10: 4–13. [Shestakova M.V., Vikulova O.K., Zheleznyakova A.V. et al. Diabetes epidemiology in Russia: what has changed over the decade? Therapevticheskiy arkhiv. 2019; 10: 4–13 (In Russ.)]. doi: 10.26442/00403660.2019.10.000364.

  3. Dailey G. Overall mortality in diabetes mellitus: where do we stand today? Diabetes Technol Ther. 2011; 13(Suppl 1): S65–S74. doi: 10.1089/dia. 2011.0019.

  4. Rosano G.M., Vitale C., Seferovic P. Heart failure in patients with diabetes mellitus. Card Fail Rev. 2017; 3(1): 52–55. doi: 10.15420/cfr.2016:20:2.

  5. Kristensen S.L., Preiss D., Jhund P.S. et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016; 9(1): e002560. doi: 10.1161/CIRCHEARTFAILURE.115.002560.

  6. Nincevic V., Omanovic Kolaric T., Roguljic H. et al Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes. Int J Mol Sci. 2019; 20(23): 5831. doi: 10.3390/ijms20235831.

  7. Adler A.I., Stevens R.J., Manley S.E. et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003; 63(1): 225–32. doi: 10.1046/j.1523-1755.2003.00712.x.

  8. Gerstein H.C., Mann J.F.E., Yi Q. et al. HOPE study investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001; 286(4): 421–26. doi: 10.1001/jama.286.4.421.

  9. Mann J.F.E., Gerstein H.C., Pogue J. et al. HOPE investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001; 134(8): 629–36. doi: 10.7326/0003-4819-134-8-200104170-00007.

  10. Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant. 2002; 17 Suppl 11: 50–54. doi: 10.1093/ndt/17.suppl_11.50.

  11. Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология. 2005; 3: 7–15. [Smirnov A.V., Dobronravov V.A., Kayukov I.G. Cardiorenal continuum, pathogenetical grounds of preventive nephrology. Nefrologiya. 2005; 3: 7–15 (In Russ.)].

  12. Кобалава Ж.Д., Моисеев В.С., Ефремовцева М.А. Кардиоренометаболический синдром – краеугольный камень современной кардиологии. Вестник РУДН. Серия: медицина. 2008; 6: 16–21. [Kobalava Zh.D., Moiseev V.S., Efremovtseva M.A. Cardiorenometabolic syndrome - the cornerstone of modern cardiology. Vestnik RUDN: Meditdina. 2008; 6: 16–21 (In Russ.)].

  13. Saxon D.R., Reiter-Brennan C., Blaha M.J., Eckel R.H. Cardiometabolic medicine: development of a new subspecialty. J Clin Endocrinol Metab. 2020; 105(7): 1–10. doi:10.1210/clinem/dgaa261.

  14. Wiviott S.D., Raz I., Bonaca M.P. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347–57. doi: 10.1056/NEJMoa1812389.

  15. Инструкция по медицинскому применению лекарственного препарата Форсига с учетом изменений 1–4. РУ: ЛП 002596 от 13.07.20 г. http://grls.rosminzdrav.ru/ (дата обращения – 01.11.2020). [Instructions for the medical use of Forsiga, taking into account changes 1–4. http://grls.rosminzdrav.ru/ (date of access – 01.11.2020) (In Russ.)].

  16. Rhee J.J., Jardine M.J., Chertow G.M., Mahaffey K.W. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes Obes Metab. 2020; 22 Suppl 1: 46–54. doi: 10.1111/dom.13987.

  17. FDA: Guidance for industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. URL: https://www.federalregister.gov/documents/2008/12/19/E8-30086/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic (date of access – 01.11.2020).

  18. Shao S.C., Lin Y.H., Chang K.C. et al. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients? BMJ Open Diabetes Res Care. 2019; 7(1): e000742. doi: 10.1136/bmjdrc-2019-000742.

  19. Varas-Lorenzo C., Margulis A.V., Pladevall M. et al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord. 2014; 14: 129. doi: 10.1186/1471-2261-14-129.

  20. Roumie C.L., Min J.Y., D'Agostino McGowan L. et al. Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study. J Am Heart Assoc. 2017; 6(4): e005379. doi: 10.1161/JAHA.116.005379.

  21. Kluger A.Y., Tecson K.M., Barbin C.M. et al. Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review. Rev Cardiovasc Med. 2018; 19(2): 41–49. doi: 10.31083/j.rcm.2018.02.907.

  22. Furtado R.H.M., Bonaca M.P., Raz I. et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation. 2019; 139(22): 2516–27. doi: 10.1161/CIRCULATIONAHA.119.039996.

  23. Wheeler D.C., Stefansson B.V., Batiushin M. et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020; 35(10): 1700–11. doi: 10.1093/ndt/gfaa234.

  24. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск. Сахарный диабет. 2019; S1–1: 1–144. [Dedov I.I., Shestakova M.V., Mayorov A.Y. et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Sakharniy diabet. 2019; S1–1: 1–144 (In Russ.)].

  25. Patel D.K., Strong J. The pleotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Ther. 2019; 10(5): 1771–92. doi: 10.1007/s13300-019-00686-z.

  26. Tamargo J. Sodium-glucose cotransporter 2 inhibitors in heart failure: potential mechanisms of action, adverse effects and future developments. Eur Cardiol. 2019; 14(1): 23–32. doi: 10.15420/ecr.2018.34.2.

  27. Verma S., McMurray J.J.V., Cherney D.Z.I. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol. 2017; 2(9): 939–40. doi: 10.1001/jamacardio.2017.1891.

  28. Verma S., McMurray J.J.V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018; 61(10): 2108–17. doi: 10.1007/s00125-018-4670-7.

  29. Wende A.R., Brahma M.K., McGinnis G.R. et al. Metabolic origins of heart failure. JACC Basic Transl Sci. 2017; 2(3): 297–310. doi: 10.1016/j.jacbts.2016.11.009.

  30. Ferrannini E., Mark M., Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a «thrifty substrate» hypothesis. Diabetes Care. 2016; 39(7): 1108–14. doi: 10.2337/dc16-0330.

  31. Verma S., Rawat S., Ho K.L. et al. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci. 2018; 3(5): 575–87. doi: 10.1016/j.jacbts.2018.07.006.

  32. Garcia-Ropero A., Santos-Gallego C.G., Zafar M.U. et al. Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opin Drug Metab Toxicol. 2019; 15(4): 275–85. doi: 10.1080/17425255.2019.1588886.

  33. Packer M., Anker S.D., Butler J. et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017; 2(9): 1025–29. doi: 10.1001/jamacardio.2017.2275.

  34. Uthman L., Baartscheer A., Schumacher C.A. et al. Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol. 2018; 9: 1575. doi: 10.3389/fphys.2018.01575.

  35. House A.A., Wanner C., Sarnak M.J. et al. Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019; 95(6): 1304–17. doi: 10.1016/j.kint.2019.02.022.


About the Autors

Tatyana Yu. Demidova, MD, professor, head of the Department of endocrinology, faculty of general medicine of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 109263, Moscow, 4/1 Shkuleva Str. E-mail: t.y.demidova@gmail.com. ORCID: 0000-0001-6385-540X
Svetlana G. Zenina, assistant of the Department of endocrinology, faculty of general medicine of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 109263, Moscow, 4/1 Shkuleva Str. E-mail: shurpesha@mail.ru

Back to Content

Бионика Медиа